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ABSTRACT
Objectives: The aim is to detect clinical and ultrasonographic characters that predict the response of adenomyosis to levonorgestrel-releasing 
intrauterine system (LNG-IUS) and to evaluate the clinical efficacy and the time needed to show a response.
Methods: A prospective single-arm study conducted in the Obstetrics and Gynaecology Department Al-Yarmouk Teaching Hospital in Baghdad/Iraq 
from August 2015 to March 2018. Women with symptomatic adenomyosis with age 39 years and above and who completed their families had been 
enrolled in this study. LNG-IUS was used as a treatment; the outcome measure was to evaluate its effect in improving the symptoms and the time 
needed to show a clinical response. Multivariate analysis was used to assess the contribution of the clinical and ultrasonographic parameters to the 
prediction of the response to LNG-IUS.
Results: Over the mean duration of follow-up period of the study (22.7±9.9 months), there was a significant improvement in menstrual blood loss, 
dysmenorrhea, and hemoglobin (Hb) with significant decrease in uterine volume (p˂0.001). The time to show response was as early as 3 months and 
the first 6 months is the best time to predict failure. Initial menstrual blood loss and Hb were good predictors to show response while uterine volume 
an excellent one (positive predictive value 80% and negative predictive value 97.2%).
Conclusion: Levonorgestrel-releasing intrauterine device is an effective treatment of symptomatic adenomyosis in term of time to response and 
duration of response. The presenting Hb, menstrual blood loss, and uterine volume are useful predictors of response.
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INTRODUCTION
Adenomyosis of the uterus is a common condition among women in 
their 4th and 5th decades of life and is thought to affect 1% of women [1]. 
It occurs when there is a disruption in the normal interface between the 
endometrial basal layer and the myometrium, causing the invasion of 
ectopic endometrial glands into the myometrium. This invasion can be 
either diffuse (adenomyosis) or focal (adenomyoma) [2].
A reliable diagnose of adenomyosis can be made by the combination 
of clinical history, gynecological examination, and transvaginal 2D 
and 3D ultrasound. In addition, Doppler sonography and magnetic 
resonance imaging might help to determine adenomyosis, especially 
in cases with combined uterine fibroids [3]. The diagnosis depends 
on triad of clinical manifestations composed of the abnormal uterine 
bleeding (50%), secondary dysmenorrhea (30%), and an enlarged, 
tender uterus [4].
Hysterectomy was previously recommended as a definitive treatment 
for adenomyosis; however, this may not be acceptable to some 
patients [5]. A reversible medical treatment alternative to hysterectomy 
does now exist the levonorgestrel-releasing intrauterine system (LNG-
IUS). This device has been widely evaluated in terms of contraceptive 
efficacy and idiopathic menorrhagia, and it is highly effective in the 
treatment of hydroxymethylbutyrate in perimenopausal women and 
has been shown to be extremely effective in treating the symptoms 
associated with adenomyosis [6,7]. Moreover, LNG-IUS seems to 
demonstrate significant and comparable improvements in hemoglobin 
(Hb) levels to hysterectomy in treating symptomatic adenomyosis, and 
although both of them lead to improvements in health-related quality 
of life, LNG-IUS seems to have superior effects on psychosocial life [8].
LNG-IUS had been effectively used to treat adenomyosis through a 
reduction in thickness of the myometrial junctional zone and total uterine 
volume [9–11]. The reduction of menstrual blood loss is due to both 
direct effect of levonorgestrel on adenomyosis foci with decidualization 
and an increase in apoptosis in endometrial glands and stroma [12].
The LNG-IUS has fewer side effects in comparison to other oral 
treatment used, in contrast with relatively low serum levels, locally high 
concentrations of LNG in the endometrium and adjacent tissues [13].
Factors that can predict LNG-IUS treatment response or discontinuation 
due to expulsion or failure to show a response in women with 
adenomyosis were not well assessed [5,14].
The aim of this study was to detect clinical and ultrasonographic 
characters that predict the response of adenomyosis to LNG-IUS and 
to evaluate the clinical efficacy and the time needed to show response.
MATERIALS AND METHODS
A prospective single-arm study conducted in the Obstetrics and 
Gynaecology Department Al-Yarmouk Teaching Hospital in Baghdad/
Iraq from August 2015 to March 2018 after ethical and scientific 
committee approval of the Obstetrics and Gynaecology Department.
Women with adenomyosis diagnosed clinically and by ultrasound 
had been recruited after taking informed written consent from all 
participants; patients with symptomatic adenomyosis, age 39 years and 
above and who completed their families had been enrolled in this study. 
Women with concomitant leiomyomas and other uterine pathology had 
been excluded as well as women who did not complete their family.
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Detailed history, examination, and baseline Hb were performed for all 
participant followed by ultrasound (transabdominal and transvaginal) 
to confirm the diagnosis of adenomyosis and exclude other concomitant 
uterine pathology.
Pictorial blood loss assessment chart was used to assess menstrual 
blood loss/cycle and menorrhagia defined when the chart score was 
more than 100 which was, in turn, equivalent to blood loss of more than 
80 mL [15].
The severity of dysmenorrhea and pelvic pain was graded by a 10 cm 
visual analog pain scale (VAS), where mild pain = 1–3, moderate = 4–6, 
sever= 7–9, and sever disabling pain=10 [16].
The ultrasound features used to diagnose adenomyosis in this study 
were the presence of myometrial cysts, linear myometrial striations, 
poor delineation of the endomyometrial junction, heterogeneous 
myometrium, and a globular and/or asymmetric uterus [17]. Uterine 
volume based on the sonographic parameters was calculated using 
the formula for a prolate ellipsoidals; Volume = 0.5233 × D1 × D2 × D3 
where, D1 = maximum length (longitudinal dimension), D2 = maximum 
AP dimension, and D3 = maximum width (transverse dimension) [14]. 
All the patients were subjected to an outpatient endometrial biopsy to 
rule out other associated possible endometrial pathology [18].
LNG-IUS (Mirena-Bayer, Germany) was inserted in the uterus at the 
end of the cycle by a specialist in strict accordance with the operating 
instructions and its place in utero was confirmed immediately by 
ultrasound and reconfirmed again 10–14 days after.
Medical management using nonsteroidal anti-inflammatory drugs, 
antifibrinolytics tranexamic acid if not contraindicated for the first 
2–3 months with cycle was given, and anemia was assessed and 
corrected [19].
Each patient was asked to come for regular follow-up after Mirena 
insertion 3 m, 6 m and then at the end of 1st year and 2nd year was full 
history to see the clinical response regarding menstrual blood loss and 
pain score and to notify any possible encountered side effect. At each 
visit, transabdominal and transvaginal ultrasound was done to measure 
the uterine volume and to confirm that the Mirena is in place and not 
partially or completely displaced.
Failure was defined as expulsion or discontinuation of Mirena use due 
to failure to show a response or because of its side effects.
Statistical analysis
Anderson darling test was to assess normality of data, Chi-square 
test, or Fisher exact test used to analyze the discrete variables. Two 
independent samples t-test used to analyze the differences in means 
between two groups, for paired group paired t-test was used (normally 
distributed data), while Wilcoxon U test used for non-normally 
distributed data. Receiver operator curve used to assess the validity 
of different parameters. SPSS 20.0.0 (Chicago, IL), MedClac 14.8.1, 
and GraphPad Prism 7.0 software package used to make the statistical 
analysis, p value considered when appropriate to be significant if <0.05
RESULTS
A total of 46 women with symptomatic adenomyosis were evaluated. 
The basic clinical characters of the participants are shown in Table 1. 
The mean age of the women was 44.5±2.5 (39–49) years, and the mean 
number of parity was 3.6±0.9 (2–6). Before insertion of LNG-IUS, the 
mean menstrual blood loss using PMAC was 144.1±25.9 ml, mean pain 
3.65±1.04 using VAS, and the mean uterine volume was 139.8±33.2.
After insertion of LNG-IUS - there was a significant reduction in bleeding 
volume from baseline to 3 months (144.1±25.9 to 123.5±29.0), there 
was significant reduction from 3 months to 6 months after using Marina 
(70.2±12.7), there was again significant reduction from 6 months 
to 12 months after using Marina (28.2±8.3), and finally there was 
significant further reduction from 12 months to 24 months after using 
Marina (25.9±7.1), as illustrated in Fig. 1.
There was significant reduction in median dysmenorrhea from VAS (3-4) 
to (2-3), there was significant change in medina VAS score from 3 months 
to 6 months after using Marina 2 (1–2), there was significant change 
in median VAS score from 6 months to 12 months after using Marina 
0 (0–1), and finally there was no significant change from 12 months to 
24 months after using Marina 0 (0–1), as illustrated in Fig. 2.
At baseline uterine volume was 131.8±25.5 mm3 which reduced 
significantly to 111.1±22.3 mm3 after 6 months, after 12 months of 
using Mirena it reduced significantly to 93.4±14.2 mm3 and finally after 
another 12 months (2 years) it continue to reduced significantly to 
82.3±10.1 mm3, as illustrated in Fig. 3.
There was a significant increase in Hb value from baseline to the end of 
follow-up (10.3±0.4–11.3±0.7, p<0.001), as illustrated in Fig. 4.
Table 2 shows the final outcome at the end of the study with a mean 
duration of follow-up 22.7±9.9 months. The success rate was 80.4%, 
Table 1: Basic clinical characteristics
Variables Value
Number 46
Age (years), mean±SD (range) 44.5±2.5 (39–49)
Parity, mean±SD (range) 3.6±0.9 (2–6)
BMI, mean±SD (range) 26.1±1.8 (22–29)
Bleeding volume, mean±SD (range) 144.1±25.9 (100–200)
Dysmenorrhea, mean±SD (range) 3.65±1.04 (2–6)
Mild dysmenorrhea, n (%) 19 (41.3)
Moderate dysmenorrhea, n (%) 27 (58.7%)
Uterine volume, mean±SD (range) 139.8±33.2 (90–240)
Past surgical history, n (%)
Curettage, n (%) 8 (17.4)
CS, n (%) 9 (19.6)
Others, n (%) 1 (2.2)
SD: Standard deviation, range (minimum – maximum)
Table 2: Final outcome at the end of the study
Variables Value
Final outcome
Success implantation, n (%) 37 (80.4)
Failure, n (%) 9 (19.6)
Duration of follow-up (months), mean±SD (range) 22.7±9.9 (3–32)
Hysterectomy, n (%) 4 (8.7)
SD: Standard deviation, range (minimum – maximum)
Fig. 1: Change in bleeding volume
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and the failure rate was 19.6% (expulsion+failure to show response), 
4 of them end up with hysterectomy and histopathology then after 
confirm the diagnosis of adenomyosis.
Bleeding volume and uterine volume at baseline were significantly 
higher in patients with failure outcome; baseline Hb was significantly 
lower in patients with failure outcome; as illustrated in Table 3.
Bleeding volume and Hb had good ability to predict failure of 
implantation, while uterine volume had excellent ability to predict 
failure. Bleeding volume above 160 had high positive predictive value 
(PPV) which indicates it will more 45% increase in the post-test 
probability for predicting failure, uterine volume above 155 had also 
strong increase in predicting failure, and baseline Hb had slight increase 
in the post-test probability for predicting failure of implantation, as 
illustrated in Table 4 and Fig. 5. Duration of ≤6 months best predict 
failure of treatment, as illustrated in Table 4.
DISCUSSION
LNG-IUS is used as an effective treatment reducing adenomyosis-
associated menorrhagia with a significant increase in Hb, hematocrit, 
and serum ferritin [11,20,21]
In our study, there was a significant reduction in bleeding volume/
cycle 3 months, 6 months, 1 year, and continue to decrease 2 years 
after insertion of Mirena. Dysmenorrhea also showed significant 
improvement 3, 6 months, and 1 year after Mirena insertion. Clinical 
response was assessed objectively by significant improvement in Hb 
level throughout the follow-up period.
On the other hand, uterine volume decreased significantly in the first 
6 months of using Mirena and continues to decrease significantly over 
the 1st and 2nd year - the period of the study. This result was in agreed 
with Lee et al. who showed that mean uterine volume decreased in 
patients with adenomyosis 6 months after Mirena insertion as well 
as it shows significant improvement in the VAS and PABC scores [22]. 
However, Cho et al. study revealed that the efficacy of the LNG-IUS on 
uterine volume may begin to decrease in 2 years after its insertion [14].
Fig. 2: Boxplot of the change in dysmenorrhea using visual analog 
pain scale score
Fig. 3: Uterine volume change during the treatment periods
Fig. 4: Change in hemoglobin in the study
Fig. 5: ROC curve of the predictors of failure of implantation 
Table 3: Comparison between different variables in relation to 




Age, mean±SD 44.0±2.1 44.6±2.6 0.546
Parity, mean±SD 3.4±0.9 3.7±0.9 0.509
BMI, mean±SD 26.6±1.1 26.0±2.0 0.399
Bleeding volume, mean±SD 176.7±21.8 136.2±20.0 <0.001
Dysmenorrhea score, 
median (IQR)
4 (3 – 4) 4 (3 – 4) 0.839
Uterine volume baseline, 
mean±SD
182.2±35.3 129.5±23.3 <0.001
Baseline Hb, mean±SD 10.0±0.2 10.3±0.3 <0.001
SD: Standard deviation
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The current study shows a success rate of 80.4% and the failure rate of 
19.6% (9 patients out of 46 patients - 8 of them had expulsion of the device, 
and one showed failure of response) and duration of ≤6 months best time 
to predict failure after LNG-IUD insertion. Lee et al. study showed a failure 
rate of about 21.6 % and median time to failure was 6.7 months [22]. Merki–
Feld et al. [23] and Socolov et al. [24] showed 15% and 10.7% failure rate, 
respectively, and that decreased within 1 year after LNG-IUD insertion.
Factors that can predict LNG-IUD treatment response or discontinuation 
due to expulsion or failure to show a response in women with 
adenomyosis were not well assessed [5,14].
In our study, we use multivariate analysis to detect possible factors that 
can predict response to Mirena before its use in adenomyosis.
This analysis showed that the bleeding volume and Hb had good ability to 
predict failure of implantation, while uterine volume had excellent ability 
to predict failure. Bleeding volume above 160 had high PPV - with more 
than 45% increase in the post-test probability for predicting failure.
Uterine volume above 155 cm³ had also strong increase in predicting 
failure. The cutoff value of more than 155 cm³ was similar to that seen 
by Lee et al. study which showed that the optimum cutoff value of 
uterine volume of ˃150 cm³ was significantly associated with LNG-IUD 
failure [22]. Zhang et al., on the other hand, used the uterine volume of 
180 cm³ as a cutoff level to predict failure [25].
CONCLUSION
LNG-IUS is an effective option in treating symptomatic adenomyosis in 
term of time to response and duration of response. The presenting Hb, 
menstrual blood loss, and uterine volume are useful predictors of response.
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